Interleukin-2 receptor antibody induction with early low dose tacrolimus preserves post-liver transplant renal function in at risk individuals
dc.contributor.author | Nayagam, JS | |
dc.contributor.author | Tavabie, OD | |
dc.contributor.author | Norton, B | |
dc.contributor.author | McMahon, MJS | |
dc.contributor.author | Ramos, K | |
dc.contributor.author | Cadden, ISH | |
dc.contributor.author | Cramp, Matthew | |
dc.contributor.author | Menon, K | |
dc.contributor.author | Prachalias, A | |
dc.contributor.author | Agarwal, K | |
dc.contributor.author | Heneghan, MA | |
dc.contributor.author | Joshi, D | |
dc.contributor.author | Aluvihare, VR | |
dc.date.accessioned | 2022-02-25T13:03:19Z | |
dc.date.available | 2022-02-25T13:03:19Z | |
dc.date.issued | 2021-07 | |
dc.identifier.issn | 2666-9676 | |
dc.identifier.other | 100028 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/18846 | |
dc.description.abstract |
Background Renal dysfunction post liver transplantation (LT) is common. We report our real-world experience of IL2Ra induction with immediate exposure to reduced dose tacrolimus used for patients with chronic kidney disease (CKD) and evolving acute kidney injury (AKI). Method A single-centre retrospective analysis of elective adult LT from 1/1/17 to 31/12/17. The primary outcome measure was increase in CKD stage at month 6 post-LT, and secondary outcome was early biopsy proven acute rejection (BPAR). Results 161 patients were included: 17 planned-IL2Ra for CKD; 38 unplanned-IL2Ra for AKI; and 106 standard immunosuppression. IL2Ra group had lower trough tacrolimus levels till month 3 post-LT. Patients receiving IL2Ra did not have an increased risk of increase in CKD class at month 6 (aOR 0.95, 95% CI 0.34–2.75, P = 0.92), or of early BPAR (aOR 0.53, 95% CI 0.19–1.32, P = 0.19). Conclusion IL2Ra induction with immediate exposure to reduced dose tacrolimus can be given to patients with CKD or early evolving AKI post-LT, with no greater attrition of renal function at 6 months or an increased risk of early BPAR when compared to standard IS. Longer-term outcome data is required, however this regimen can be considered for high risk LT recipients with CKD and AKI. | |
dc.format.extent | 100028-100028 | |
dc.language | en | |
dc.language.iso | en | |
dc.publisher | Elsevier BV | |
dc.subject | Kidney Disease | |
dc.subject | Organ Transplantation | |
dc.subject | Clinical Research | |
dc.subject | Prevention | |
dc.subject | Transplantation | |
dc.subject | 6.4 Surgery | |
dc.subject | Renal and urogenital | |
dc.title | Interleukin-2 receptor antibody induction with early low dose tacrolimus preserves post-liver transplant renal function in at risk individuals | |
dc.type | journal-article | |
plymouth.volume | 3 | |
plymouth.publication-status | Published | |
plymouth.journal | Journal of Liver Transplantation | |
dc.identifier.doi | 10.1016/j.liver.2021.100028 | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Faculty of Health/Peninsula Medical School | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/Research Groups | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED) | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR | |
plymouth.organisational-group | /Plymouth/Users by role | |
plymouth.organisational-group | /Plymouth/Users by role/Academics | |
dcterms.dateAccepted | 2021-07-21 | |
dc.rights.embargodate | 2022-2-26 | |
dc.rights.embargoperiod | Not known | |
rioxxterms.versionofrecord | 10.1016/j.liver.2021.100028 | |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2021-07 | |
rioxxterms.type | Journal Article/Review |